Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
ALERT: The links for the podcasts are now fixed.
Here's the question and answer session with Drs. Mary Pinder and Nasser Hanna following their presentations on the lung cancer highlights from the ASCO 2011 annual meeting (Dr. Pinder's on SCLC, early stage NSCLC, and mesothelioma here, and Dr. Hanna's on advanced NSCLC here), covering a lot of ground on timely issues raised from the conference. The program and podcast were developed in partnership with LUNGevity Foundation.
Below is the audio and video versions of the podcast, as well as the transcript and figures.
[powerpress]
asco-2011-highlights-in-lung-cancer-qa-audio-podcast
asco-2011-highlights-in-lung-cancer-qa-session-transcript
asco-2011-highlights-in-lung-cancer-qa-session-figures
But if that list of questions and answers doesn't cover every question YOU have in response to the ASCO presentations, feel free to ask the stragglers here.
Please feel free to offer comments and raise questions in our
discussion forums.
Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...
The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)
There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...
Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.
The...
Biomarkers are genetic mutations (like EGFR, ALK, KRAS, BRAF) or protein levels (like PD-L1) in tumor cells that help guide personalized treatment, especially NSCLC, directing patients to targeted therapies or immunotherapies...
Hi Stan! So good to hear from you. I'm sorry for the late response. I too have been out of town with family and missed your post, probably because I was...
It is so good to hear from you! And I am so happy to hear that your holidays have been good and that you are doing well. It sounds like your...
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components: